4 top lessons the Theranos scandal can teach us as investors 

The Theranos story presents a timely reminder of some age-old investment wisdom that can help me avoid some basic stock-picking pitfalls.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I, like many of you, will be watching the gripping miniseries, The Dropout. It unpacks one of the most bizarre cases of corporate fraud you will ever see. By a blood-testing start-up called Theranos, no less.

The company managed to dupe many high-profile investors. It shows me that I am never too old to learn an investment lesson.

Putting the Theranos case study into context

So, in 2014 Elizabeth Holmes was a 30-year-old billionaire. She had founded a company valued at $9bn (£6.5bn) for supposedly bringing about a revolution in diagnosing disease.

The only problem? The technology didn’t work.

Soon enough, Holmes was exposed as a fake. In honour of the high-profile debacle, here are five lessons from the Theranos story that continue to serve me well in my investment journey. 

Always evaluate the track record of the management team

Firstly, a big clue is in the title of the miniseries – The Dropout. The fact the CEO of the start-up was a university dropout with no track record in the medical industry is an immediate red flag for me.

The saying goes, “there are no bad companies, only bad managers.” To invest, I must believe beyond doubt that the management team are competent and know what they are doing. Otherwise, I don’t!

Don’t worry about other people

As with many trends in life, herd theory occurs in finance when investors follow the crowd instead of their own analysis. In the case of Theranos, the crowd included bigwigs like Larry Ellison and Henry Kissinger. But, no matter how clever I believe my potential co-investors are, it will never be enough to convince me to invest in a stock. At least not unless I have justified this with my own view.

I never invest in businesses that I do not understand

At one point Theranos claimed to be able to perform all manner of tests, ranging from cholesterol levels to complex genetic analysis. All with just a single pinprick of blood.

Admittedly, I am no geneticist, and haven’t met many. This, in all likelihood, means that I will not understand complex genetic analysis. That is my personal signal to avoid investment.

If I don’t understand a stock, I do not invest in it.

I avoid concentration risk at all costs

Concentration risk occurs when I rely too much on a single investment; for example, a single company’s shares.

So, my prime objective is to avoid an over-reliance on a particular stock or security. My portfolio could be exposed to severe losses if the company goes bust. This turned out to be the reality for many an investor in Theranos.

As such, I counter this by spreading my investment risk by diversifying across sectors, asset classes and regions.

I will never invest in a business I do not understand

In conclusion, investment sage Warren Buffett once said “never invest in a business you cannot understand”. This is the rule I have found to be the most important in my stock-picking journey.

As an investor, independent thought and analysis has served me well.

In the end, I’d rather blame myself for my investment mistake, than someone like Elizabeth Holmes.

Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Illustration of flames over a black background
Investing Articles

Recently released: December’s higher-risk, high-reward stock recommendation [PREMIUM PICKS]

Fire ideas will tend to be more adventurous and are designed for investors who can stomach a bit more volatility.

Read more »

Abstract 3d arrows with rocket
Growth Shares

Will the SpaceX IPO send this FTSE 100 stock into orbit?

How can British investors get exposure to SpaceX? Here is one FTSE 100 stock that might be perfect for those…

Read more »

Array of piggy banks in saturated colours on high colour contrast background
Investing Articles

Could drip-feeding £500 into the FTSE 250 help you retire comfortably?

Returns from FTSE 250 shares have rocketed to 10.6% over the last year. Is now the time to plough money…

Read more »

Passive and Active: text from letters of the wooden alphabet on a green chalk board
Investing Articles

How much does one need in an ISA for £2,056 monthly passive income?

The passive income potential of the Stocks and Shares ISA is higher than perhaps all other investments. Here's how the…

Read more »

Finger clicking a button marked 'Buy' on a keyboard
Investing Articles

The best time to buy stocks is when they’re cheap. Here’s 1 from my list

Buying discounted stocks can be a great way to build wealth and earn passive income. But investors need to be…

Read more »

Bus waiting in front of the London Stock Exchange on a sunny day.
Investing Articles

Martin Lewis just explained the stock market’s golden rule

Unlike cash, the stock market can quietly turn lump sums into serious wealth. So, what’s the secret sauce that makes…

Read more »

Close-up of British bank notes
Investing Articles

£5,000 invested in Greggs shares at the start of 2025 is now worth…

This year's been extremely grim for FTSE 250-listed Greggs -- but having slumped more than 40%, could its shares be…

Read more »

Investing Articles

Looking for shares to buy as precious metals surge? 3 things to remember!

Gold prices have been on a tear. So has silver. So why isn't this writer hunting for shares to buy…

Read more »